Aprotinin
Trasylol (aprotinin) is an unknown pharmaceutical. Aprotinin was first approved as Trasylol on 1993-12-29. It is used to treat hemorrhage in the USA. The pharmaceutical is active against plasminogen.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hemorrhage | MP_0001914 | D006470 | R58 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
aprotinin, Trasylol, Bayer HealthCare Pharmaceuticals Inc. | |||
| 2100-12-29 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | 1 | 1 | 3 | 6 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | 3 | 4 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | 1 | 1 | 2 |
| Pancreatic fistula | D010185 | — | — | — | — | — | 1 | — | 1 |
| Fistula | D005402 | — | — | — | — | — | 1 | — | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | 1 | — | 1 |
| Leiomyoma | D007889 | — | D25 | — | — | — | 1 | — | 1 |
| Myofibroma | D047708 | — | — | — | — | — | 1 | — | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Surgical blood loss | D016063 | — | — | — | — | 4 | — | — | 4 |
| Postoperative hemorrhage | D019106 | — | — | — | — | 2 | — | 1 | 3 |
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | — | 1 | — | — | 1 |
| Transcatheter aortic valve replacement | D065467 | — | — | — | — | 1 | — | — | 1 |
| Blood transfusion | D001803 | — | — | — | — | 1 | — | — | 1 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gallstones | D042882 | EFO_0004210 | — | 1 | 1 | — | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Pathologic processes | D010335 | — | — | — | 1 | — | — | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | — | 1 | — | — | — | 1 |
| Fatigue | D005221 | — | R53.83 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | 1 | 2 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | 2 | — | — | — | — | 2 |
| Thrombosis | D013927 | — | — | 1 | — | — | — | — | 1 |
| Cholelithiasis | D002769 | EFO_0004799 | K80 | 1 | — | — | — | — | 1 |
| Cholecystolithiasis | D041761 | EFO_1000864 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiac surgical procedures | D006348 | — | — | — | — | — | — | 3 | 3 |
| Cardiopulmonary bypass | D002315 | — | — | — | — | — | — | 2 | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
| Adenoma | D000236 | — | — | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Septic shock | D012772 | — | A48.3 | — | — | — | — | 1 | 1 |
| Shock | D012769 | — | R57.1 | — | — | — | — | 1 | 1 |
| Glucagonoma | D005935 | — | — | — | — | — | — | 1 | 1 |
| Seroma | D049291 | — | — | — | — | — | — | 1 | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aprotinin |
| INN | aprotinin |
| Description | Pancreatic trypsin inhibitor precursor (Basic protease inhibitor) (BPI) |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 1B0C, 1EAW, 1EJM, 1G6X, 1OA5, 1OA6, 1P2I, 1P2J, 1P2K, 1P2M, 1P2N, 1P2O, 1P2Q, 1QLQ, 1T7C, 1T8L, 1T8M, 1T8N, 1T8O, 1UUA, 1UUB, 1YKT, 1YLC, 1YLD, 2FI3, 2FI4, 2FI5, 2FTL, 2FTM, 2IJO, 2R9P, 2RA3, 2TPI, 2ZJX, 2ZVX, 3FP6, 3FP7, 3FP8, 3GYM, 3LDI, 3LDJ, 3LDM, 3OTJ, 3P92, 3P95, 3U1J, 4BNR, 4DG4, 4WWY, 4WXV, 4Y0Y, 4Y0Z, 4Y10, 4Y11, 5JB4, 5JB5, 5JB6, 5JB7, 5XX2, 5XX3, 5XX4, 5XX5, 5XX6, 5XX7, 5XX8, 5YVU, 6F1F, 7PH1, 7QIQ, 7QIR, 7QIS, 7QIT |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201619 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06692 |
| UNII ID | 04XPW8C0FL (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 77,384 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,399 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use